GENERIC NAME OF THE MEDICINAL PRODUCT:

Perindopril Erbumine 2mg
Perindopril Erbumine 4mg
Perindopril Erbumine 8mg

QUALITATIVE AND QUANTITATIVE COMPOSITION:

a) Perindopril Erbumine Tablets 2mg
Each uncoated tablet contains:
Perindopril Erbumine ………….…2mg
Excipients……………………………. q.s.
Colours: Iron oxide red

b) Perindopril Erbumine Tablets 4mg
Each uncoated tablet contains:
Perindopril Erbumine …………….4mg
Excipients…………………….………q.s.
Colours: Sunset Yellow.

C) Perindopril Erbumine Tablets 8mg
Each uncoated tablet contains:
Perindopril Erbumine…………….8mg
Excipients…………………….………q.s.
Colours: Iron oxide Yellow.

THERAPEUTIC INDICATIONS:

Perindopril Erbumine is indicated for the control of hyperphosphatasemia in adult patients receiving hemodialysis or peritoneal dialysis.
Perindopril Erbumine is also indicated for the control of hyperphosphatasemia in adult patients with chronic kidney disease (CKD) not on dialysis with serum phosphorus ≥ 1.78 mmol/l.

CAUTION & WARNING:

CAUTION:
Read enclosed leaflet before use.
KEEP MEDICINE OUT OF REACH OF CHILDREN.
SWALLOW WHOLE DO NOT CHEW OR CRUSH
SCHEDULE “H” Prescription Drug -Warning: Not to be sold by retail without the prescription of a Registered Medical Prescriber.

STORAGE & DOSAGE:

Storage: Protect form moisture at a temperature not exceeding 25˚C. Do not freeze. Keep container in a well-ventilated place. Keep away from sources of ignition and heat
Dosage: As directed by the Physician.

Perindopril Erbumine  4mg Technical Specification:

Product Name:
 Perindopril Erbumine
Brand Name: Generics
Strength: 2mg, 4mg, 8mg
Dosage Form: Tablets (Uncoated)
Route of Administration: Via oral Route
Packing: 30s, 90s,100s
Pack Insert/Leaflet: PIL (Patient Information Leaflet)
Regulatory Documents: COA, MOA,Stability Studies, GMP
Therapeutic use: Antihypertension, ACE inhibitor
Indication: Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction.
Storage: Protect form moisture at a temperature not exceeding 25˚C.Do not freeze. Keep the container tightly closed in order to protect from moisture.

GENERIC NAME OF THE MEDICINAL PRODUCT:

  • Perindopril Erbumine 2mg
  • Perindopril Erbumine 4mg
  • Perindopril Erbumine 8mg

QUALITATIVE AND QUANTITATIVE COMPOSITION:

  • a) Perindopril Erbumine Tablets 2mg
    Each uncoated tablet contains:
    Perindopril Erbumine ………….…2mg
    Excipients……………………………. q.s.
    Colours: Iron oxide red
  • b) Perindopril Erbumine Tablets 4mg
    Each uncoated tablet contains:
    Perindopril Erbumine…………….4mg
    Excipients…………………….………q.s.
    Colours: Sunset Yellow.
  • C) Perindopril Erbumine Tablets 8mg
    Each uncoated tablet contains:
    Perindopril Erbumine…………….8mg
    Excipients…………………….………q.s.
    Colours: Iron oxide Yellow.

THERAPEUTIC INDICATIONS:

  • Perindopril Erbumine is indicated for the control of hyperphosphatasemia in adult patients receiving hemodialysis or peritoneal dialysis.
    Perindopril Erbumine is also indicated for the control of hyperphosphatasemia in adult patients with chronic kidney disease (CKD) not on dialysis with serum phosphorus ≥ 1.78 mmol/l.  

CAUTION & WARNING:

  • CAUTION:
    Read enclosed leaflet before use.
    Keep medicine out of reach of children.
    SWALLOW WHOLE DO NOT CHEW OR CRUSH
  • SCHEDULE “H” Prescription Drug-Warning: Not to be sold by retail without the prescription of a Registered Medical Prescriber.

STORAGE & DOSAGE:

  • Storage:Protect form moisture at a temperature not exceeding 25˚C. Do not freeze.Keep container in a well-ventilated place. Keep away from sources of ignition and heat
  • Dosage:  As directed by the Physician.